shutterstock_399778786_paul_brady_photography
Paul Brady Photography / Shutterstock.com
15 November 2022AmericasStaff Writer

FTC wades into escalating ‘Orange Book’ clash

Jazz accused a rival of infringement | Avadel filed a counterclaim seeking to delist the patent from the Orange Book.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
16 November 2021   Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem.
Americas
22 December 2022   Delisting affects a blockbuster narcolepsy drug | Orange book has specific listing criteria | Avadel.

More on this story

Americas
16 November 2021   Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem.
Americas
22 December 2022   Delisting affects a blockbuster narcolepsy drug | Orange book has specific listing criteria | Avadel.

More on this story

Americas
16 November 2021   Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem.
Americas
22 December 2022   Delisting affects a blockbuster narcolepsy drug | Orange book has specific listing criteria | Avadel.